CliffBio
small molecule

TEMOZOLOMIDE

TEMOZOLOMIDE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameTEMOZOLOMIDE
Active ingredientTEMOZOLOMIDE
Strength140MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.